Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection

Tan et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2021.700502
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 24 countries.
No treatment is 100% effective. Protocols combine treatments.
5,400+ studies for 118 treatments. c19ivm.org
In Vitro study showing highly synergistic antiviral activity of the combination of ivermectin and remdesivir against murine coronavirus (MHV) infection in RAW264.7 macrophages. Authors found that while remdesivir monotherapy (6 μM) achieved a 2-log10 reduction in live virus, the combination with ivermectin (2 μM) demonstrated exceptional synergy, producing a striking 7-log10 reduction in viral load and 2.5-log10 reduction in viral RNA. The remdesivir-ivermectin combination also significantly reduced pro-inflammatory cytokine levels (IL-6, TNF-α, and LIF) that are associated with the "cytokine storm" in severe COVID-19. Ivermectin exhibited the highest selectivity index among tested drugs, indicating a favorable safety profile. Authors suggest this synergistic combination could potentially target different mechanisms in the viral lifecycle while providing both antiviral and anti-inflammatory benefits for coronavirus infections.
73 preclinical studies support the efficacy of ivermectin for COVID-19:
Ivermectin, better known for antiparasitic activity, is a broad spectrum antiviral with activity against many viruses including H7N770, Dengue36,71,72, HIV-172, Simian virus 4073, Zika36,74,75, West Nile75, Yellow Fever76,77, Japanese encephalitis76, Chikungunya77, Semliki Forest virus77, Human papillomavirus56, Epstein-Barr56, BK Polyomavirus78, and Sindbis virus77.
Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins70,72,73,79, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing37, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination40,80, shows dose-dependent inhibition of wildtype and omicron variants35, exhibits dose-dependent inhibition of lung injury60,65, may inhibit SARS-CoV-2 via IMPase inhibition36, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation9, inhibits SARS-CoV-2 3CLpro53, may inhibit SARS-CoV-2 RdRp activity28, may minimize viral myocarditis by inhibiting NF-κB/p65-mediated inflammation in macrophages59, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation81, may interfere with SARS-CoV-2's immune evasion via ORF8 binding4, may inhibit SARS-CoV-2 by disrupting CD147 interaction82-85, shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-1958,86, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage8, may minimize SARS-CoV-2 induced cardiac damage39,47, may disrupt SARS-CoV-2 N and ORF6 protein nuclear transport and their suppression of host interferon responses1, increases Bifidobacteria which play a key role in the immune system87, has immunomodulatory50 and anti-inflammatory69,88 properties, and has an extensive and very positive safety profile89.
Study covers remdesivir and ivermectin.
Tan et al., 30 Jul 2021, USA, peer-reviewed, 4 authors. Contact: micctk@nus.edu.sg.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperIvermectinAll
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection
Yu Ling Tan, Kevin S W Tan, Justin Jang Hann Chu, Vincent T Chow
Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2021.700502
The recent COVID-19 pandemic has highlighted the urgency to develop effective antiviral therapies against the disease. Murine hepatitis virus (MHV) is a coronavirus that infects mice and shares some sequence identity to SARS-CoV-2. Both viruses belong to the Betacoronavirus genus, and MHV thus serves as a useful and safe surrogate model for SARS-CoV-2 infections. Clinical trials have indicated that remdesivir is a potentially promising antiviral drug against COVID-19. Using an in vitro model of MHV infection of RAW264.7 macrophages, the safety and efficacy of monotherapy of remdesivir, chloroquine, ivermectin, and doxycycline were investigated. Of the four drugs tested, remdesivir monotherapy exerted the strongest inhibition of live virus and viral RNA replication of about 2-log 10 and 1-log 10 , respectively (at 6 µM). Ivermectin treatment showed the highest selectivity index. Combination drug therapy was also evaluated using remdesivir (6 µM) together with chloroquine (15 µM), ivermectin (2 µM) or doxycycline (15 µM)above their IC50 values and at high macrophage cell viability of over 95%. The combination of remdesivir and ivermectin exhibited highly potent synergism by achieving significant reductions of about 7-log 10 of live virus and 2.5-log 10 of viral RNA in infected macrophages. This combination also resulted in the lowest cytokine levels of IL-6, TNF-a, and leukemia inhibitory factor. The next best synergistic combination was remdesivir with doxycycline, which decreased levels of live virus by ~3-log 10 and viral RNA by ~1.5-log 10 . These results warrant further studies to explore the mechanisms of action of the combination therapy, as well as future in vivo experiments and clinical trials for the treatment of SARS-CoV-2 infection.
AUTHOR CONTRIBUTIONS VC and YT conceptualized and designed the research project, and analyzed the data. All experiments were carried out by YT. All authors contributed to the article and approved the submitted version. SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2021. 700502/full#supplementary-material Supplementary Figure 1 Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aaron, Ferris, Henry, Speert, Macdonald, Multiple Combination Bactericidal Antibiotic Testing for Patients With Cystic Fibrosis Infected With Burkholderia Cepacia, Am. J. Respir. Crit. Care Med, doi:10.1164/ajrccm.161.4.9907147
Agostini, Andres, Sims, Graham, Sheahan et al., Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease, mBio, doi:10.1128/mBio.00221-18
Ahmed, Karim, Ross, Hossain, Clemens et al., A Five-Day Course of Ivermectin for the Treatment of COVID-19 may Reduce the Duration of Illness, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.191
Bafna, White, Harish, Rosales, Ramelot et al., Hepatitis C Virus Drugs That Inhibit SARS-CoV-2 Papain-Like Protease Synergize With Remdesivir to Suppress Viral Replication in Cell Culture, Cell Rep, doi:10.1016/j.celrep.2021.109133
Bakowski, Beutler, Wolff, Kirkpatrick, Chen et al., Drug Repurposing Screens Identify Chemical Entities for the Development of COVID-19 Interventions, Nat. Commun, doi:10.1038/s41467-021-23328-0
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19 -Final Report, N. Engl. J. Med, doi:10.1056/NEJMoa2007764
Bong, Brasher, Chikumba, Mcdougall, Mellin-Olsen et al., The COVID-19 Pandemic: Effects on Low-and Middle-Income Countries, Anesth. Analg, doi:10.1213/ANE.0000000000004846
Brenner, Rice, Anderson, Percopo, Rosenberg, Immortalized MH-S Cells Lack Defining Features of Primary Alveolar Macrophages and do Not Support Mouse Pneumovirus Replication, Immunol. Lett, doi:10.1016/j.imlet.2016.02.012
Brown, Won, Graham, Dinnon, Sims et al., Broad Spectrum Antiviral Remdesivir Inhibits Human Endemic and Zoonotic Deltacoronaviruses With a Highly Divergent RNA Dependent RNA Polymerase, Antiviral Res, doi:10.1016/j.antiviral.2019.104541
Bryant, Lawrie, Dowswell, Fordham, Mitchell et al., Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, Am. J. Ther, doi:10.1097/MJT.0000000000001402
Caly, Druce, Catton, Jans, Wagstaff, The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 In Vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Chaccour, Casellas, Blanco-Di, Matteo, Pineda et al., The Effect of Early Treatment With Ivermectin on Viral Load, Symptoms and Humoral Response in Patients With non-Severe COVID-19: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
Chiow, Phoon, Putti, Tan, Chow, Evaluation of Antiviral Activities of Houttuynia Cordata Thunb. Extract, Quercetin, Quercetrin and Cinanserin on Murine Coronavirus and Dengue Virus Infection, Asian Pac J. Trop. Med, doi:10.1016/j.apjtm.2015.12.002
Choy, Wong, Kaewpreedee, Sia, Chen et al., Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication In Vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104786
Dalskov, Møhlenberg, Thyrsted, Blay-Cadanet, Poulsen et al., SARS-CoV-2 Evades Immune Detection in Alveolar Macrophages, EMBO Rep, doi:10.15252/embr.202051252
Dittmar, Lee, Whig, Segrist, Li et al., Drug Repurposing Screens Reveal Cell-Type-Specific Entry Pathways and FDA-Approved Drugs Active Against SARS-Cov-2, Cell Rep, doi:10.1016/j.celrep.2021.108959
Doern, When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing, J. Clin. Microbiol, doi:10.1128/JCM.01121-14
Dyer, Schellens, Bonville, Martin, Domachowske et al., Efficient Replication of Pneumonia Virus of Mice (PVM) in a Mouse Macrophage Cell Line, Virol. J, doi:10.1186/1743-422X-4-48
Gao, Tian, Yang, Breakthrough: Chloroquine Phosphate has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies, Biosci. Trends, doi:10.5582/bst.2020.01047
Greco, Bravo, Parsons, The Search for Synergy: A Critical Review From a Response Surface Perspective, Pharmacol. Rev
Hamming, Timens, Bulthuis, Lely, Navis et al., Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis, J. Pathol, doi:10.1002/path.1570
Hojyo, Uchida, Tanaka, Hasebe, Tanaka et al., How COVID-19 Induces Cytokine Storm With High Mortality, Inflamm. Regen, doi:10.1186/s41232-020-00146-3
Jeffreys, Pennington, Duggan, Breen, Jinks et al., Remdesivir-Ivermectin Combination Displays Synergistic Interaction With Improved In Vitro Antiviral Activity Against SARS-CoV-2, bioRxiv, doi:10.1101/2020.12.23.424232
Kalil, Patterson, Mehta, Tomashek, Wolfe et al., Baricitinib Plus Remdesivir for Hospitalized Adults With Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2031994
Kinobe, Owens, A Systematic Review of Experimental Evidence for Antiviral Effects of Ivermectin and an in Silico Analysis of Ivermectin's Possible Mode of Action Against SARS-CoV-2, Fundam. Clin. Pharmacol, doi:10.1111/fcp.12644
Klok, Kruip, Van Der Meer, Arbous, Gommers et al., Incidence of Thrombotic Complications in Critically Ill ICU Patients With COVID-19, Thromb. Res, doi:10.1016/j.thromres.2020.04.013
Krolewiecki, Lifschitz, Moragas, Travacio, Valentini et al., Antiviral Effect of High-Dose Ivermectin in Adults With COVID-19: A Proof-of-Concept Randomized Trial, EClinicalMedicine, doi:10.1016/j.eclinm.2021.100959
Loṕez-Medina, Loṕez, Hurtado, Davalos, Ramirez et al., Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2021.3071
Lv, Wang, Qu, Zhu, Zhu et al., Distinct Uptake, Amplification, and Release of SARS-CoV-2 by M1 and M2 Alveolar Macrophages, Cell Discov, doi:10.1038/s41421-021-00258-1
Malmgaard, Melchjorsen, Bowie, Mogensen, Paludan, Viral Activation of Macrophages Through TLR-Dependent and -Independent Pathways, J. Immunol, doi:10.4049/jimmunol.173.11.6890
Martin, Neal, Mcbride, Palmenberg, Mengovirus and Encephalomyocarditis Virus Poly(C) Tract Lengths can Affect Virus Growth in Murine Cell Culture, J. Virol, doi:10.1128/jvi.74.7.3074-3081.2000
Merad, Martin, Pathological Inflammation in Patients With COVID-19: A Key Role for Monocytes and Macrophages, Nat. Rev. Immunol, doi:10.1038/s41577-020-0331-4
Mondal, Quintili, Karamchandani, Bose, Thromboembolic Disease in COVID-19 Patients: A Brief Narrative Review, J. Intensive Care, doi:10.1186/s40560-020-00483-y
Murali-Krishna, Ravi, Manjunath, Japanese Encephalitis Virus Infection of Mouse Cell Lines: Ability to Prime Mice for Generation of Virus Specific Cytotoxic T Lymphocytes and Differences in CTL Recognisable Viral Determinants, Arch. Virol, doi:10.1007/BF01309728
Narasaraju, Tang, Herrmann, Muller, Chow et al., Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19, Front. Pharmacol, doi:10.3389/fphar.2020.00870
Nativel, Couret, Giraud, Meilhac, Hellencourt et al., Porphyromonas Gingivalis Lipopolysaccharides Act Exclusively Through TLR4 With a Resilience Between Mouse and Human, Sci. Rep, doi:10.1038/s41598-017-16190-y
Ng, Narasaraju, Phoon, Sim, Seet et al., Doxycycline Treatment Attenuates Acute Lung Injury in Mice Infected With Virulent Influenza H3N2 Virus: Involvement of Matrix Metalloproteinases, Exp. Mol. Pathol, doi:10.1016/j.yexmp.2012.03.003
Park, Macrophages: A Trojan Horse in COVID-19?, Nat. Rev. Immunol, doi:10.1038/s41577-020-0317-2
Pope, Marsden, Cole, Sloan, Fung et al., Resistance to Murine Hepatitis Virus Strain 3 Is Dependent on Production of Nitric Oxide, J. Virol, doi:10.1128/JVI.72.9.7084-7090.1998
Satarker, Ahuja, Banerjee, Balaji, Dogra et al., Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2, Curr. Pharmacol. Rep, doi:10.1007/s40495-020-00231-8
Seet, Quek, Ooi, Sengupta, Lakshminarasappa et al., Positive Impact of Oral Hydroxychloroquine and Povidone-Iodine Throat Spray for COVID-19 Prophylaxis: An Open-Label Randomized Trial, Int. J. Infect. Dis, doi:10.1016/j.ijid.2021.04.035
Sharma, Ahmad Farouk, Lal, COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention, Viruses, doi:10.3390/v13020202
Sharma, Ong, Loke, Chua, Lee et al., Comparative Transcriptomic and Molecular Pathway Analyses of HL-CZ Human Pro-Monocytic Cells Expressing SARS-CoV-2 Spike S1, S2, NP, NSP15 and NSP16 Genes, Microorganisms, doi:10.3390/microorganisms9061193
Shi, Luo, Wang, Horst, Bläsius et al., M1 But Not M0 Extracellular Vesicles Induce Polarization of RAW264.7 Macrophages via the TLR4-Nfkb Pathway In Vitro, Inflammation, doi:10.1007/s10753-020-01236-7
Shirato, Kizaki, SARS-CoV-2 Spike Protein S1 Subunit Induces Pro-Inflammatory Responses via Toll-Like Receptor 4 Signaling in Murine and Human Macrophages, Heliyon, doi:10.1016/j.heliyon.2021.e06187
Sica, Erreni, Allavena, Porta, Macrophage Polarization in Pathology, Cell. Mol. Life Sci, doi:10.1007/s00018-015-1995-y
Smith, Tse, Read, Liu, Regulation of Macrophage Polarization and Plasticity by Complex Activation Signals, Integr. Biol, doi:10.1039/c6ib00105j
Sun, Pan, Qu, Xu, Dou et al., 17b-Estradiol Promotes Trained Immunity in Females Against Sepsis Via Regulating Nucleus Translocation of RelB, Front. Immunol, doi:10.3389/fimmu.2020.01591
Sun, Sanderson, Zheng, Drug Combination Therapy Increases Successful Drug Repositioning, Drug Discov. Today, doi:10.1016/j.drudis.2016.05.015
Tang, Liu, Zhang, Xu, Ji et al., Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies, Front. Immunol, doi:10.3389/fimmu.2020.01708
Traber, Symer, Allen, Kim, Hilliard et al., Myeloid-Epithelial Cross Talk Coordinates Synthesis of the Tissue-Protective Cytokine Leukemia Inhibitory Factor During Pneumonia, Am. J. Physiol. Lung Cell. Mol. Physiol, doi:10.1152/ajplung.00482.2016
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a Potent Inhibitor of SARS Coronavirus Infection and Spread, Virol. J, doi:10.1186/1743-422X-2-69
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a Specific Inhibitor of Importin a/b-Mediated Nuclear Import Able to Inhibit Replication of HIV-1 and Dengue Virus, Biochem. J, doi:10.1042/BJ20120150
Wang, Ye, Ye, Li, Gao et al., Up-Regulation of IL-6 and TNF-Alpha Induced by SARS-Coronavirus Spike Protein in Murine Macrophages Via NF-KappaB Pathway, Virus Res, doi:10.1016/j.virusres.2007.02.007
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in Adults With Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Wu, Liu, Yang, Zhang, Zhong et al., Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods, Acta Pharm. Sin. B, doi:10.1016/j.apsb.2020.02.008
Wölfel, Corman, Guggemos, Seilmaier, Zange et al., Virological Assessment of Hospitalized Patients With COVID-2019, Nature, doi:10.1038/s41586-020-2196-x
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The Broad Spectrum Antiviral Ivermectin Targets the Host Nuclear Transport Importin a/b1 Heterodimer, Antiviral Res, doi:10.1016/j.antiviral.2020.104760
Yates, Newman, Oshry, Glassman, Leone et al., Doxycycline Treatment of High-Risk COVID-19-Positive Patients With Comorbid Pulmonary Disease, Ther. Adv. Respir. Dis, doi:10.1177/1753466620951053
Zheng, Monteil, Maurer-Stroh, Yew, Leong et al., Monoclonal Antibodies for the S2 Subunit of Spike of SARS-CoV-1 Cross-React With the Newly-Emerged SARS-CoV-2, Euro. Surveill, doi:10.2807/1560-7917.ES.2020.25.28.2000291
DOI record: { "DOI": "10.3389/fcimb.2021.700502", "ISSN": [ "2235-2988" ], "URL": "http://dx.doi.org/10.3389/fcimb.2021.700502", "abstract": "<jats:p>The recent COVID-19 pandemic has highlighted the urgency to develop effective antiviral therapies against the disease. Murine hepatitis virus (MHV) is a coronavirus that infects mice and shares some sequence identity to SARS-CoV-2. Both viruses belong to the <jats:italic>Betacoronavirus </jats:italic>genus, and MHV thus serves as a useful and safe surrogate model for SARS-CoV-2 infections. Clinical trials have indicated that remdesivir is a potentially promising antiviral drug against COVID-19. Using an<jats:italic>in vitro</jats:italic>model of MHV infection of RAW264.7 macrophages, the safety and efficacy of monotherapy of remdesivir, chloroquine, ivermectin, and doxycycline were investigated. Of the four drugs tested, remdesivir monotherapy exerted the strongest inhibition of live virus and viral RNA replication of about 2-log<jats:sub>10</jats:sub>and 1-log<jats:sub>10</jats:sub>, respectively (at 6 µM). Ivermectin treatment showed the highest selectivity index. Combination drug therapy was also evaluated using remdesivir (6 µM) together with chloroquine (15 µM), ivermectin (2 µM) or doxycycline (15 µM) – above their IC50 values and at high macrophage cell viability of over 95%. The combination of remdesivir and ivermectin exhibited highly potent synergism by achieving significant reductions of about 7-log<jats:sub>10</jats:sub>of live virus and 2.5-log<jats:sub>10</jats:sub>of viral RNA in infected macrophages. This combination also resulted in the lowest cytokine levels of IL-6, TNF-α, and leukemia inhibitory factor. The next best synergistic combination was remdesivir with doxycycline, which decreased levels of live virus by ~3-log<jats:sub>10</jats:sub>and viral RNA by ~1.5-log<jats:sub>10</jats:sub>. These results warrant further studies to explore the mechanisms of action of the combination therapy, as well as future<jats:italic>in vivo</jats:italic>experiments and clinical trials for the treatment of SARS-CoV-2 infection.</jats:p>", "alternative-id": [ "10.3389/fcimb.2021.700502" ], "author": [ { "affiliation": [], "family": "Tan", "given": "Yu Ling", "sequence": "first" }, { "affiliation": [], "family": "Tan", "given": "Kevin S. W.", "sequence": "additional" }, { "affiliation": [], "family": "Chu", "given": "Justin Jang Hann", "sequence": "additional" }, { "affiliation": [], "family": "Chow", "given": "Vincent T.", "sequence": "additional" } ], "container-title": "Frontiers in Cellular and Infection Microbiology", "container-title-short": "Front. Cell. Infect. Microbiol.", "content-domain": { "crossmark-restriction": true, "domain": [ "frontiersin.org" ] }, "created": { "date-parts": [ [ 2021, 7, 30 ] ], "date-time": "2021-07-30T16:51:27Z", "timestamp": 1627663887000 }, "deposited": { "date-parts": [ [ 2023, 1, 5 ] ], "date-time": "2023-01-05T23:31:03Z", "timestamp": 1672961463000 }, "indexed": { "date-parts": [ [ 2024, 9, 12 ] ], "date-time": "2024-09-12T18:33:08Z", "timestamp": 1726165988944 }, "is-referenced-by-count": 22, "issued": { "date-parts": [ [ 2021, 7, 30 ] ] }, "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 7, 30 ] ], "date-time": "2021-07-30T00:00:00Z", "timestamp": 1627603200000 } } ], "link": [ { "URL": "https://www.frontiersin.org/articles/10.3389/fcimb.2021.700502/full", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1965", "original-title": [], "prefix": "10.3389", "published": { "date-parts": [ [ 2021, 7, 30 ] ] }, "published-online": { "date-parts": [ [ 2021, 7, 30 ] ] }, "publisher": "Frontiers Media SA", "reference": [ { "DOI": "10.1164/ajrccm.161.4.9907147", "article-title": "Multiple Combination Bactericidal Antibiotic Testing for Patients With Cystic Fibrosis Infected With Burkholderia Cepacia", "author": "Aaron", "doi-asserted-by": "publisher", "first-page": "1206", "journal-title": "Am. J. Respir. Crit. Care Med.", "key": "B1", "volume": "161", "year": "2000" }, { "DOI": "10.1128/mBio.00221-18", "article-title": "Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease", "author": "Agostini", "doi-asserted-by": "publisher", "first-page": "e00221", "journal-title": "mBio", "key": "B2", "volume": "9", "year": "2018" }, { "DOI": "10.1016/j.ijid.2020.11.191", "article-title": "A Five-Day Course of Ivermectin for the Treatment of COVID-19 may Reduce the Duration of Illness", "author": "Ahmed", "doi-asserted-by": "publisher", "first-page": "214", "journal-title": "Int. J. Infect. Dis.", "key": "B3", "volume": "103", "year": "2021" }, { "DOI": "10.1016/j.celrep.2021.109133", "article-title": "Hepatitis C Virus Drugs That Inhibit SARS-CoV-2 Papain-Like Protease Synergize With Remdesivir to Suppress Viral Replication in Cell Culture", "author": "Bafna", "doi-asserted-by": "publisher", "journal-title": "Cell Rep.", "key": "B4", "volume": "35", "year": "2021" }, { "DOI": "10.1038/s41467-021-23328-0", "article-title": "Drug Repurposing Screens Identify Chemical Entities for the Development of COVID-19 Interventions", "author": "Bakowski", "doi-asserted-by": "publisher", "first-page": "3309", "journal-title": "Nat. Commun.", "key": "B5", "volume": "12", "year": "2021" }, { "DOI": "10.1056/NEJMoa2007764", "article-title": "Remdesivir for the Treatment of Covid-19 - Final Report", "author": "Beigel", "doi-asserted-by": "publisher", "first-page": "1813", "journal-title": "N. Engl. J. Med.", "key": "B6", "volume": "383", "year": "2020" }, { "DOI": "10.1213/ANE.0000000000004846", "article-title": "The COVID-19 Pandemic: Effects on Low- and Middle-Income Countries", "author": "Bong", "doi-asserted-by": "publisher", "first-page": "86", "journal-title": "Anesth. Analg.", "key": "B7", "volume": "131", "year": "2020" }, { "DOI": "10.1016/j.imlet.2016.02.012", "article-title": "Immortalized MH-S Cells Lack Defining Features of Primary Alveolar Macrophages and do Not Support Mouse Pneumovirus Replication", "author": "Brenner", "doi-asserted-by": "publisher", "first-page": "106", "journal-title": "Immunol. Lett.", "key": "B8", "volume": "172", "year": "2016" }, { "DOI": "10.1016/j.antiviral.2019.104541", "article-title": "Broad Spectrum Antiviral Remdesivir Inhibits Human Endemic and Zoonotic Deltacoronaviruses With a Highly Divergent RNA Dependent RNA Polymerase", "author": "Brown", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res.", "key": "B9", "volume": "169", "year": "2019" }, { "DOI": "10.1097/MJT.0000000000001402", "article-title": "Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines", "author": "Bryant", "doi-asserted-by": "publisher", "first-page": "e434", "journal-title": "Am. J. Ther.", "key": "B10", "volume": "28", "year": "2021" }, { "DOI": "10.1016/j.antiviral.2020.104787", "article-title": "The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 In Vitro", "author": "Caly", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res.", "key": "B11", "volume": "178", "year": "2020" }, { "DOI": "10.1016/j.eclinm.2020.100720", "article-title": "The Effect of Early Treatment With Ivermectin on Viral Load, Symptoms and Humoral Response in Patients With non-Severe COVID-19: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial", "author": "Chaccour", "doi-asserted-by": "publisher", "journal-title": "EClinicalMedicine", "key": "B12", "volume": "32", "year": "2021" }, { "DOI": "10.1016/j.apjtm.2015.12.002", "article-title": "Evaluation of Antiviral Activities of Houttuynia Cordata Thunb. Extract, Quercetin, Quercetrin and Cinanserin on Murine Coronavirus and Dengue Virus Infection", "author": "Chiow", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Asian Pac J. Trop. Med.", "key": "B13", "volume": "9", "year": "2016" }, { "DOI": "10.1016/j.antiviral.2020.104786", "article-title": "Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication In Vitro", "author": "Choy", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res.", "key": "B14", "volume": "178", "year": "2020" }, { "DOI": "10.15252/embr.202051252", "article-title": "SARS-CoV-2 Evades Immune Detection in Alveolar Macrophages", "author": "Dalskov", "doi-asserted-by": "publisher", "journal-title": "EMBO Rep.", "key": "B15", "volume": "21", "year": "2020" }, { "DOI": "10.1016/j.celrep.2021.108959", "article-title": "Drug Repurposing Screens Reveal Cell-Type-Specific Entry Pathways and FDA-Approved Drugs Active Against SARS-Cov-2", "author": "Dittmar", "doi-asserted-by": "publisher", "journal-title": "Cell Rep.", "key": "B16", "volume": "35", "year": "2021" }, { "DOI": "10.1128/JCM.01121-14", "article-title": "When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing", "author": "Doern", "doi-asserted-by": "publisher", "first-page": "4124", "journal-title": "J. Clin. Microbiol.", "key": "B17", "volume": "52", "year": "2014" }, { "DOI": "10.1186/1743-422X-4-48", "article-title": "Efficient Replication of Pneumonia Virus of Mice (PVM) in a Mouse Macrophage Cell Line", "author": "Dyer", "doi-asserted-by": "publisher", "first-page": "48", "journal-title": "Virol. J.", "key": "B18", "volume": "4", "year": "2007" }, { "DOI": "10.5582/bst.2020.01047", "article-title": "Breakthrough: Chloroquine Phosphate has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies", "author": "Gao", "doi-asserted-by": "publisher", "first-page": "72", "journal-title": "Biosci. Trends", "key": "B19", "volume": "14", "year": "2020" }, { "article-title": "The Search for Synergy: A Critical Review From a Response Surface Perspective", "author": "Greco", "first-page": "331", "journal-title": "Pharmacol. Rev.", "key": "B20", "volume": "47", "year": "1995" }, { "DOI": "10.1002/path.1570", "article-title": "Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis", "author": "Hamming", "doi-asserted-by": "publisher", "first-page": "631", "journal-title": "J. Pathol.", "key": "B21", "volume": "203", "year": "2004" }, { "DOI": "10.1186/s41232-020-00146-3", "article-title": "How COVID-19 Induces Cytokine Storm With High Mortality", "author": "Hojyo", "doi-asserted-by": "publisher", "first-page": "37", "journal-title": "Inflamm. Regen.", "key": "B22", "volume": "40", "year": "2020" }, { "DOI": "10.1101/2020.12.23.424232", "article-title": "Remdesivir-Ivermectin Combination Displays Synergistic Interaction With Improved In Vitro Antiviral Activity Against SARS-CoV-2", "author": "Jeffreys", "doi-asserted-by": "crossref", "key": "B23", "volume-title": "bioRxiv.", "year": "2020" }, { "DOI": "10.1056/NEJMoa2031994", "article-title": "Baricitinib Plus Remdesivir for Hospitalized Adults With Covid-19", "author": "Kalil", "doi-asserted-by": "publisher", "first-page": "795", "journal-title": "N. Engl. J. Med.", "key": "B24", "volume": "384", "year": "2021" }, { "DOI": "10.1111/fcp.12644", "article-title": "A Systematic Review of Experimental Evidence for Antiviral Effects of Ivermectin and an in Silico Analysis of Ivermectin’s Possible Mode of Action Against SARS-CoV-2", "author": "Kinobe", "doi-asserted-by": "publisher", "first-page": "260", "journal-title": "Fundam. Clin. Pharmacol.", "key": "B25", "volume": "35", "year": "2021" }, { "DOI": "10.1016/j.thromres.2020.04.013", "article-title": "Incidence of Thrombotic Complications in Critically Ill ICU Patients With COVID-19", "author": "Klok", "doi-asserted-by": "publisher", "first-page": "145", "journal-title": "Thromb. Res.", "key": "B26", "volume": "191", "year": "2020" }, { "DOI": "10.1016/j.eclinm.2021.100959", "article-title": "Antiviral Effect of High-Dose Ivermectin in Adults With COVID-19: A Proof-of-Concept Randomized Trial", "author": "Krolewiecki", "doi-asserted-by": "publisher", "journal-title": "EClinicalMedicine", "key": "B27", "volume": "37", "year": "2021" }, { "DOI": "10.1001/jama.2021.3071", "article-title": "Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial", "author": "López-Medina", "doi-asserted-by": "publisher", "first-page": "1426", "journal-title": "JAMA", "key": "B28", "volume": "325", "year": "2021" }, { "DOI": "10.1038/s41421-021-00258-1", "article-title": "Distinct Uptake, Amplification, and Release of SARS-CoV-2 by M1 and M2 Alveolar Macrophages", "author": "Lv", "doi-asserted-by": "publisher", "first-page": "24", "journal-title": "Cell Discov.", "key": "B29", "volume": "7", "year": "2021" }, { "DOI": "10.4049/jimmunol.173.11.6890", "article-title": "Viral Activation of Macrophages Through TLR-Dependent and -Independent Pathways", "author": "Malmgaard", "doi-asserted-by": "publisher", "first-page": "6890", "journal-title": "J. Immunol.", "key": "B30", "volume": "173", "year": "2004" }, { "DOI": "10.1128/jvi.74.7.3074-3081.2000", "article-title": "Mengovirus and Encephalomyocarditis Virus Poly(C) Tract Lengths can Affect Virus Growth in Murine Cell Culture", "author": "Martin", "doi-asserted-by": "publisher", "first-page": "3074", "journal-title": "J. Virol.", "key": "B31", "volume": "74", "year": "2000" }, { "DOI": "10.1038/s41577-020-0331-4", "article-title": "Pathological Inflammation in Patients With COVID-19: A Key Role for Monocytes and Macrophages", "author": "Merad", "doi-asserted-by": "publisher", "first-page": "355", "journal-title": "Nat. Rev. Immunol.", "key": "B32", "volume": "20", "year": "2020" }, { "DOI": "10.1186/s40560-020-00483-y", "article-title": "Thromboembolic Disease in COVID-19 Patients: A Brief Narrative Review", "author": "Mondal", "doi-asserted-by": "publisher", "first-page": "70", "journal-title": "J. Intensive Care", "key": "B33", "volume": "8", "year": "2020" }, { "DOI": "10.1007/BF01309728", "article-title": "Japanese Encephalitis Virus Infection of Mouse Cell Lines: Ability to Prime Mice for Generation of Virus Specific Cytotoxic T Lymphocytes and Differences in CTL Recognisable Viral Determinants", "author": "Murali-Krishna", "doi-asserted-by": "publisher", "first-page": "127", "journal-title": "Arch. Virol.", "key": "B34", "volume": "140", "year": "1995" }, { "DOI": "10.3389/fphar.2020.00870", "article-title": "Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19", "author": "Narasaraju", "doi-asserted-by": "publisher", "journal-title": "Front. Pharmacol.", "key": "B35", "volume": "11", "year": "2020" }, { "DOI": "10.1038/s41598-017-16190-y", "article-title": "Porphyromonas Gingivalis Lipopolysaccharides Act Exclusively Through TLR4 With a Resilience Between Mouse and Human", "author": "Nativel", "doi-asserted-by": "publisher", "first-page": "15789", "journal-title": "Sci. Rep.", "key": "B36", "volume": "7", "year": "2017" }, { "DOI": "10.1016/j.yexmp.2012.03.003", "article-title": "Doxycycline Treatment Attenuates Acute Lung Injury in Mice Infected With Virulent Influenza H3N2 Virus: Involvement of Matrix Metalloproteinases", "author": "Ng", "doi-asserted-by": "publisher", "first-page": "287", "journal-title": "Exp. Mol. Pathol.", "key": "B37", "volume": "92", "year": "2012" }, { "DOI": "10.1038/s41577-020-0317-2", "article-title": "Macrophages: A Trojan Horse in COVID-19", "author": "Park", "doi-asserted-by": "publisher", "first-page": "351", "journal-title": "Nat. Rev. Immunol.", "key": "B38", "volume": "20", "year": "2020" }, { "DOI": "10.1128/JVI.72.9.7084-7090.1998", "article-title": "Resistance to Murine Hepatitis Virus Strain 3 Is Dependent on Production of Nitric Oxide", "author": "Pope", "doi-asserted-by": "publisher", "first-page": "7084", "journal-title": "J. Virol.", "key": "B39", "volume": "72", "year": "1998" }, { "DOI": "10.1007/s40495-020-00231-8", "article-title": "Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2", "author": "Satarker", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Curr. Pharmacol. Rep.", "key": "B40", "volume": "24", "year": "2020" }, { "DOI": "10.1016/j.ijid.2021.04.035", "article-title": "Positive Impact of Oral Hydroxychloroquine and Povidone-Iodine Throat Spray for COVID-19 Prophylaxis: An Open-Label Randomized Trial", "author": "Seet", "doi-asserted-by": "publisher", "first-page": "314", "journal-title": "Int. J. Infect. Dis.", "key": "B41", "volume": "106", "year": "2021" }, { "DOI": "10.3390/v13020202", "article-title": "COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention", "author": "Sharma", "doi-asserted-by": "publisher", "first-page": "202", "journal-title": "Viruses", "key": "B42", "volume": "13", "year": "2021" }, { "DOI": "10.3390/microorganisms9061193", "article-title": "Comparative Transcriptomic and Molecular Pathway Analyses of HL-CZ Human Pro-Monocytic Cells Expressing SARS-CoV-2 Spike S1, S2, NP, NSP15 and NSP16 Genes", "author": "Sharma", "doi-asserted-by": "publisher", "first-page": "1193", "journal-title": "Microorganisms", "key": "B43", "volume": "9", "year": "2021" }, { "DOI": "10.1007/s10753-020-01236-7", "article-title": "M1 But Not M0 Extracellular Vesicles Induce Polarization of RAW264.7 Macrophages via the TLR4-Nfκb Pathway In Vitro", "author": "Shi", "doi-asserted-by": "publisher", "first-page": "1611", "journal-title": "Inflammation", "key": "B44", "volume": "43", "year": "2020" }, { "DOI": "10.1016/j.heliyon.2021.e06187", "article-title": "SARS-CoV-2 Spike Protein S1 Subunit Induces Pro-Inflammatory Responses via Toll-Like Receptor 4 Signaling in Murine and Human Macrophages", "author": "Shirato", "doi-asserted-by": "publisher", "journal-title": "Heliyon", "key": "B45", "volume": "7", "year": "2021" }, { "DOI": "10.1007/s00018-015-1995-y", "article-title": "Macrophage Polarization in Pathology", "author": "Sica", "doi-asserted-by": "publisher", "first-page": "4111", "journal-title": "Cell. Mol. Life Sci.", "key": "B46", "volume": "72", "year": "2015" }, { "DOI": "10.1039/c6ib00105j", "article-title": "Regulation of Macrophage Polarization and Plasticity by Complex Activation Signals", "author": "Smith", "doi-asserted-by": "publisher", "first-page": "946", "journal-title": "Integr. Biol.", "key": "B47", "volume": "8", "year": "2016" }, { "DOI": "10.3389/fimmu.2020.01591", "article-title": "17β-Estradiol Promotes Trained Immunity in Females Against Sepsis Via Regulating Nucleus Translocation of RelB", "author": "Sun", "doi-asserted-by": "publisher", "journal-title": "Front. Immunol.", "key": "B48", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.drudis.2016.05.015", "article-title": "Drug Combination Therapy Increases Successful Drug Repositioning", "author": "Sun", "doi-asserted-by": "publisher", "first-page": "1189", "journal-title": "Drug Discov. Today", "key": "B49", "volume": "21", "year": "2016" }, { "DOI": "10.3389/fimmu.2020.01708", "article-title": "Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies", "author": "Tang", "doi-asserted-by": "publisher", "journal-title": "Front. Immunol.", "key": "B50", "volume": "11", "year": "2020" }, { "DOI": "10.1152/ajplung.00482.2016", "article-title": "Myeloid-Epithelial Cross Talk Coordinates Synthesis of the Tissue-Protective Cytokine Leukemia Inhibitory Factor During Pneumonia", "author": "Traber", "doi-asserted-by": "publisher", "first-page": "L548", "journal-title": "Am. J. Physiol. Lung Cell. Mol. Physiol.", "key": "B51", "volume": "313", "year": "2017" }, { "DOI": "10.1186/1743-422X-2-69", "article-title": "Chloroquine is a Potent Inhibitor of SARS Coronavirus Infection and Spread", "author": "Vincent", "doi-asserted-by": "publisher", "first-page": "69", "journal-title": "Virol. J.", "key": "B52", "volume": "2", "year": "2005" }, { "DOI": "10.1042/BJ20120150", "article-title": "Ivermectin is a Specific Inhibitor of Importin α/β-Mediated Nuclear Import Able to Inhibit Replication of HIV-1 and Dengue Virus", "author": "Wagstaff", "doi-asserted-by": "publisher", "first-page": "851", "journal-title": "Biochem. J.", "key": "B53", "volume": "443", "year": "2012" }, { "DOI": "10.1016/j.virusres.2007.02.007", "article-title": "Up-Regulation of IL-6 and TNF-Alpha Induced by SARS-Coronavirus Spike Protein in Murine Macrophages Via NF-KappaB Pathway", "author": "Wang", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Virus Res.", "key": "B54", "volume": "128", "year": "2007" }, { "DOI": "10.1016/S0140-6736(20)31022-9", "article-title": "Remdesivir in Adults With Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial", "author": "Wang", "doi-asserted-by": "publisher", "first-page": "1569", "journal-title": "Lancet", "key": "B55", "volume": "395", "year": "2020" }, { "DOI": "10.1038/s41586-020-2196-x", "article-title": "Virological Assessment of Hospitalized Patients With COVID-2019", "author": "Wölfel", "doi-asserted-by": "publisher", "first-page": "465", "journal-title": "Nature", "key": "B56", "volume": "581", "year": "2020" }, { "DOI": "10.1016/j.apsb.2020.02.008", "article-title": "Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods", "author": "Wu", "doi-asserted-by": "publisher", "first-page": "766", "journal-title": "Acta Pharm. Sin. B", "key": "B57", "volume": "10", "year": "2020" }, { "DOI": "10.1016/j.antiviral.2020.104760", "article-title": "The Broad Spectrum Antiviral Ivermectin Targets the Host Nuclear Transport Importin α/β1 Heterodimer", "author": "Yang", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res.", "key": "B58", "volume": "177", "year": "2020" }, { "DOI": "10.1177/1753466620951053", "article-title": "Doxycycline Treatment of High-Risk COVID-19-Positive Patients With Comorbid Pulmonary Disease", "author": "Yates", "doi-asserted-by": "publisher", "journal-title": "Ther. Adv. Respir. Dis.", "key": "B59", "volume": "14", "year": "2020" }, { "DOI": "10.2807/1560-7917.ES.2020.25.28.2000291", "article-title": "Monoclonal Antibodies for the S2 Subunit of Spike of SARS-CoV-1 Cross-React With the Newly-Emerged SARS-CoV-2", "author": "Zheng", "doi-asserted-by": "publisher", "journal-title": "Euro. Surveill", "key": "B60", "volume": "25", "year": "2020" } ], "reference-count": 60, "references-count": 60, "relation": {}, "resource": { "primary": { "URL": "https://www.frontiersin.org/articles/10.3389/fcimb.2021.700502/full" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection", "type": "journal-article", "update-policy": "http://dx.doi.org/10.3389/crossmark-policy", "volume": "11" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit